HighTower Advisors’s Decoy Therapeutics DCOY Stock Holding History

HighTower Advisors’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	-$6K	–	3378
2022 Q2	$6K	Buy	+1	New	+$8.63K	﹤0.01%	3110
2022 Q1	–	Sell	-1	Closed	-$18K	–	3651
2021 Q4	$18K	Hold	1	–	–	﹤0.01%	3116
2021 Q3	$26K	Buy	+1	New	+$34.5K	﹤0.01%	2988

Other funds holding DCOY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

LNWWM

Laird Norton Wetherby Wealth Management San Francisco, California $2.45B AUM

HighTower Advisors's DCOY Position: Q3 2022 in Review

HighTower Advisors sold out of Decoy Therapeutics (DCOY) in Q3 2022, closing a stake of 1 share — an estimated $6K sold.

HighTower Advisors first reported a position in DCOY in Q3 2021 and held it in 3 quarters. The position peaked at $26K in Q3 2021. 16 funds tracked by Wall St. Rank hold DCOY as of Q3 2022.

HighTower Advisors reported no remaining Decoy Therapeutics position as of Q3 2022 after selling out during the quarter.
HighTower Advisors sold 1 Decoy Therapeutics share in Q3 2022, an estimated $6K.
HighTower Advisors first reported a position in Decoy Therapeutics in Q3 2021 and held it in 3 quarters.
HighTower Advisors's Decoy Therapeutics position peaked at $26K in Q3 2021.
16 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q3 2022.

Based on HighTower Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.